Written and maintained by CASRAI Editorial Board
Published
On this page
A viral vector vaccine uses an engineered carrier virus to deliver genetic instructions for an antigen from a target pathogen. Cells make the antigen, allowing the immune system to recognize it. Some vaccine vectors can replicate in human cells; others deliver their cargo without producing new infectious vector particles.
Short answer
The useful distinction is between the carrier virus, the antigen it encodes and the carrier’s ability to reproduce. These describe different properties. A vaccine can contain a living, engineered vector without containing the complete pathogen against which protection is sought. It can also enter cells and express antigen while being unable to complete a productive replication cycle in those cells.
The World Health Organization (WHO) describes both replicating and non-replicating vaccine vectors. For laboratory work, that classification is a starting point: the specific construct, its quality controls and the tests used to measure it still matter. ERVEBO, a recombinant vesicular stomatitis virus vaccine against Zaire ebolavirus, illustrates why the category cannot be reduced to the non-replicating adenovirus examples familiar from COVID-19.
Definition and scope
In this context, a vector is a virus used to carry an antigen-encoding sequence into cells. The antigen is the component the immune response is intended to recognize. The European Medicines Agency (EMA) calls an antigen from a different infectious agent a heterologous antigen. Its guideline allows for an entire antigen, part of one, or multiple antigens to be encoded in the vector.
The carrier and the target pathogen therefore need separate names in a clear vaccine description. In ERVEBO, the backbone is vesicular stomatitis virus (VSV), while the substituted surface glycoprotein comes from Zaire ebolavirus. The FDA prescribing information describes replacement of the VSV envelope glycoprotein with that Ebola glycoprotein. CDC explains that the vaccine contains an Ebola gene rather than the whole Ebola virus and cannot cause Ebola disease.
Viral vectors also have uses beyond vaccination. The major viral-vector types used for transgene delivery are a broader topic; the focus here is antigen delivery and immune responses. A vector’s name alone does not identify the antigen, the replication properties of the engineered construct or the evidence supporting a particular vaccine.
Similarly, “recombinant” describes genetic engineering rather than a single vaccine format. A recombinant protein vaccine and a recombinant viral vector vaccine can both use engineered biological systems, while delivering different material to the recipient. WHO’s vaccine-platform explainer distinguishes a protein subunit supplied as the antigen from genetic instructions that enable cells to make an antigen.
How a viral vector vaccine works
The central mechanism is delivery followed by antigen expression. In WHO’s explanation of viral vector COVID-19 vaccines, a virus other than the coronavirus carries a gene encoding the target antigen. After entry into a cell, the delivered instructions enable antigen production. The antigen is then recognized by the immune system. WHO describes helper T-cell and cytotoxic T-cell responses in its platform explanation and places these alongside antibody responses in its account of vaccine immunity.
Antigen production and production of new virus are separate events. A non-replicating vector can retain the functions needed for cell entry and antigen expression while lacking functions required to generate new infectious vector particles. A replicating vector can produce progeny that enter additional cells. This explains why “non-replicating” does not mean that the vaccine is unable to enter a cell or that its encoded antigen remains unexpressed.
The carrier itself also interacts with immunity. EMA’s guideline describes responses to both the inserted antigen and vector antigens, and calls for consideration of immunity already present against the vector and immunity induced by vaccination. WHO’s safety-surveillance manual likewise identifies pre-existing anti-vector immunity as relevant to assessment. A response directed against the carrier is different from the intended response to the target pathogen’s antigen; the two should not be combined into an unspecified “vaccine antibody” result.
These mechanisms do not supply a universal measure of protection. For ERVEBO, FDA states that the relative contributions of innate, antibody-mediated and cell-mediated immunity to protection are unknown, and that a protective immune-response measure is unknown. An assay can demonstrate an immune response without establishing a general threshold that proves protection for every recipient.
Types and related vaccine concepts
Replication-competent vectors
Replication-competent, or replicating, vectors can generate new vector virus in susceptible cells. This describes a biological capability, not an assertion that the engineered vaccine causes the disease it targets. CDC explicitly classifies ERVEBO as a live, attenuated, replication-competent recombinant VSV vaccine while distinguishing it from Ebola virus. Its antigen and its viral backbone must remain separate in any explanation of how it works.
Replication-defective and host-restricted vectors
Replication-defective vectors have constraints that prevent productive replication in the relevant recipient cells. EMA describes several routes to that outcome: natural host restriction, attenuation through laboratory passage and deletion of genes needed for replication. Its examples include avipox vectors, modified vaccinia Ankara (MVA) and many engineered adenovirus vectors. Those mechanisms are not interchangeable descriptions of the same genetic change.
WHO’s COVID-19 mechanism document uses non-replicating adenovirus vaccines as examples of antigen expression without production of new virus. The data table below places this example beside pox-vector restrictions and the VSV example, drawing together WHO, EMA and CDC descriptions. The table describes platform characteristics rather than current product availability, eligibility or an efficacy ranking.
Protein, nucleic-acid and whole-pathogen vaccines
A protein subunit vaccine supplies selected antigenic components rather than using a carrier virus to express them in the recipient. Nucleic-acid vaccines also provide instructions for antigen production, but WHO distinguishes direct delivery of DNA or mRNA from delivery by a viral vector. Sharing the goal of antigen expression does not make all of these the same delivery platform.
Whole-pathogen approaches are different again. WHO describes inactivated vaccines as using killed or inactivated organisms and live-attenuated vaccines as using weakened organisms. An engineered vector expressing another pathogen’s antigen can also be live and attenuated, so the word “live” alone does not resolve which organism supplies the carrier and which supplies the target antigen.
Where it matters for labs, clinics and supply decisions
Quality characterization: distinguish the attributes
EMA’s guideline separates genetic development, seed-lot characterization, manufacturing controls and final-vaccine testing. This is useful when interpreting a research report or a product’s technical documentation: a satisfactory result for one attribute does not describe every other attribute. The following checklist organizes the guideline’s recommendations; it is a reading aid rather than an experimental protocol.
- Identity: distinguish the vector from its expressed antigen. EMA recommends identity testing of both in harvested virus and identification of the final vaccine batch.
- Genetic and phenotypic stability: characterize the engineered sequence and relevant biological properties. The guideline specifically identifies regions involved in attenuation, replication deficiency, antigen expression and antigen structure.
- Potency: use a justified approach relevant to the vaccine. EMA says potency should ideally reflect vector infectivity and expression of the inserted antigen; the suitable measurement can depend on the product.
- Contamination controls: distinguish the intended vaccine virus from extraneous agents. For certain replication-defective vectors, such as defective adenovirus vaccines, testing for replication-competent virus may be necessary.
- Stability during storage: demonstrate maintenance of potency over the stated period of validity, using appropriate stability-indicating methods and justified specifications.
A particle count is therefore not automatically a complete account of biological performance. EMA discusses infectivity titres, particle numbers, their ratio when both are measured, and antigen-expression or immunogenicity approaches. It also recommends a reference preparation in potency determinations. The broader purpose of a biological assay is relevant here: the result needs to be read in relation to what the particular assay measures, rather than treating differently defined quantities as synonyms.
Cell substrates and seed lots also belong to the product description. EMA calls for characterization of production or packaging cells and documentation of master and working seed lots. FDA’s ERVEBO description, for example, identifies serum-free Vero cell cultures, purification and formulation with a stabilizer solution. That is a named product’s manufacturing description, not a production recipe that can be transferred to every vector family.
Diagnostic interpretation: the antigen can affect the test
ERVEBO provides a specific connection between vaccine design and laboratory interpretation. FDA’s prescribing information, section 7.1, warns that vaccinated individuals may test positive for anti-Ebola glycoprotein antibodies and/or Ebola glycoprotein nucleic acid or antigens. It states that glycoprotein-based testing may have limited diagnostic value during vaccine viremia, in the presence of vaccine-derived glycoprotein and following the antibody response to vaccination.
The warning concerns the test target and the vaccine’s biology. It is not a statement that every Ebola assay becomes unusable, and it does not make a positive result a diagnosis or a reason to dismiss possible infection. For laboratory documentation, the practical distinction is between a test directed at material represented in the vaccine and a result interpreted without that context. Decisions about diagnostic evaluation remain with the relevant clinical and public-health services.
Occupational protection and product-specific storage
Vaccination does not replace occupational controls. CDC states that vaccinated laboratory staff and healthcare workers at risk of Ebola exposure must continue to follow biosafety guidance and infection-prevention procedures. It also requires recommended protective equipment for vaccinated outbreak responders. A vaccine platform description cannot establish the containment or protective measures appropriate to a particular laboratory activity.
Storage is likewise a property of the particular formulation. ERVEBO’s FDA label specifies frozen storage, illustrating why a broad claim that viral vector vaccines require only ordinary refrigeration is unsuitable for the platform as a whole. For supply planning, the connection is between the named product and its documented storage conditions. This concept explainer does not substitute a generic platform rule for the product’s approved requirements.
Common misunderstandings
All viral vector vaccines are non-replicating. WHO recognizes both categories, and CDC’s classification of ERVEBO provides a concrete replication-competent example. Familiarity with a COVID-19 adenovirus platform should not be extended to all engineered vaccine viruses.
Replication-defective means biologically inactive. The relevant distinction is the ability to produce new vector virus. Entry into cells and expression of the encoded antigen are central to the non-replicating mechanism described by WHO. Replication competence also depends on the construct and the host context, as EMA’s host-restriction examples show.
Knowing the parent virus establishes the vaccine’s safety. EMA cautions that the properties of a recombinant vaccine cannot simply be predicted from the parental vector. The engineered construct, the inserted antigen and product-specific non-clinical and clinical evidence require assessment. Platform membership is not a substitute for that evidence.
A measurable antibody response guarantees protection. An immune-response assay and an established protective threshold answer different questions. FDA’s ERVEBO label makes this distinction explicit. It also warns that the vaccine may not protect everyone, so a laboratory measurement should not be turned into an unsupported individual assurance.
A vaccine against one Ebola virus covers every related virus. CDC states that ERVEBO does not protect against other orthoebolavirus species or orthomarburgviruses. The antigen’s identity is therefore part of the vaccine’s scope, alongside the carrier and replication category.
Sources
- WHO, The different types of COVID-19 vaccines. Checked 2026-11-15.
- WHO, COVID-19 vaccines and immune response, Update 73, vaccine-mechanism slides. Checked 2026-11-15.
- WHO, COVID-19 vaccines: description and general safety considerations for implementation, section 2.3. Checked 2026-11-15.
- EMA, Guideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines, EMA/CHMP/VWP/141697/2009; official TGA-hosted copy, especially sections 2, 3 and 5. Checked 2026-11-15.
- CDC, Ebola Vaccine Product Information. Checked 2026-11-15.
- FDA, ERVEBO prescribing information, especially sections 7.1, 11, 12, 14.2 and 16. Checked 2026-11-15.
Data: Vaccine vector examples: replication, antigen and source scope
Original cross-source compilation of three vaccine-vector examples. EMA descriptions of host restriction and gene deletion are combined with WHO vaccine-mechanism explanations and CDC product information. These are biological classifications, not an availability list or a ranking of safety or efficacy.
| Vector example | Replication in human recipient cells | Antigen or delivery distinction | Source and scope |
|---|---|---|---|
| Engineered adenovirus vaccine vectors with replication-gene deletions | Replication-defective | Can enter cells and express the encoded target antigen without producing new vector virus. | EMA guideline section 2; WHO Update 73 viral vector mechanism. Describes engineered vaccine vectors, not all adenoviruses. |
| Avipox vectors and modified vaccinia Ankara (MVA) | Replication restricted in humans | Avipox host restriction and MVA attenuation through passage are distinct routes to replication deficiency. | EMA guideline section 2. These are vaccine-vector examples rather than a statement that all poxviruses share this property. |
| ERVEBO recombinant vesicular stomatitis virus (VSV) | Replication-competent; live and attenuated | VSV carrier containing a gene from Ebola virus; does not contain whole Ebola virus. | CDC Ebola Vaccine Product Information. Product-specific example targeting Zaire ebolavirus. |
Sources
- EMA guideline on live recombinant viral vectored vaccines (TGA-hosted copy) (accessed 2026-11-15)
- WHO COVID-19 vaccines and immune response, Update 73 (accessed 2026-11-15)
- CDC Ebola Vaccine Product Information (accessed 2026-11-15)
Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.







